BR112012010083B8 - Composição farmacêutica tópica de liberação sustentada e uso relacionado - Google Patents

Composição farmacêutica tópica de liberação sustentada e uso relacionado

Info

Publication number
BR112012010083B8
BR112012010083B8 BR112012010083A BR112012010083A BR112012010083B8 BR 112012010083 B8 BR112012010083 B8 BR 112012010083B8 BR 112012010083 A BR112012010083 A BR 112012010083A BR 112012010083 A BR112012010083 A BR 112012010083A BR 112012010083 B8 BR112012010083 B8 BR 112012010083B8
Authority
BR
Brazil
Prior art keywords
sustained
pharmaceutical composition
topical pharmaceutical
related use
release topical
Prior art date
Application number
BR112012010083A
Other languages
English (en)
Other versions
BR112012010083A2 (pt
BR112012010083B1 (pt
Inventor
Denis Canet
Valérie Masini-Eteve
Original Assignee
Besins Healthcare Lu Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Lu Sarl filed Critical Besins Healthcare Lu Sarl
Publication of BR112012010083A2 publication Critical patent/BR112012010083A2/pt
Publication of BR112012010083B1 publication Critical patent/BR112012010083B1/pt
Publication of BR112012010083B8 publication Critical patent/BR112012010083B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Abstract

composições farmacêuticas de liberação sustentada para admi-nistração tópica e uso das mesmas. a presente invenção refere-se a composições e métodos para prover liberação sus-tentada de um agente ativo através da pele de um indivíduo, em que uma composição farmacêutica percutânea compreendendo pelo menos um éster de ácido graxo e uma quantidade terapeuticamente eficaz de agente ativo.
BR112012010083A 2009-10-27 2010-10-27 Composição farmacêutica tópica de liberação sustentada e uso relacionado BR112012010083B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25524109P 2009-10-27 2009-10-27
US61/255,241 2009-10-27
EP091787862.2 2009-12-10
EP09178762 2009-12-10
PCT/EP2010/066283 WO2011051354A2 (en) 2009-10-27 2010-10-27 Transdermal pharmaceutical compositions comprising active agents

Publications (3)

Publication Number Publication Date
BR112012010083A2 BR112012010083A2 (pt) 2020-10-27
BR112012010083B1 BR112012010083B1 (pt) 2021-05-18
BR112012010083B8 true BR112012010083B8 (pt) 2021-08-31

Family

ID=42102488

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012010083A BR112012010083B8 (pt) 2009-10-27 2010-10-27 Composição farmacêutica tópica de liberação sustentada e uso relacionado

Country Status (23)

Country Link
US (2) US10080760B2 (pt)
EP (2) EP3360575B1 (pt)
JP (1) JP5727494B2 (pt)
CN (1) CN102686240B (pt)
AU (1) AU2010311523B2 (pt)
BR (1) BR112012010083B8 (pt)
CA (1) CA2778689C (pt)
CY (1) CY1120888T1 (pt)
DK (2) DK3360575T3 (pt)
ES (2) ES2945590T3 (pt)
FI (1) FI3360575T3 (pt)
HR (2) HRP20230482T1 (pt)
HU (2) HUE039200T2 (pt)
IL (1) IL219236A (pt)
LT (2) LT3360575T (pt)
PL (2) PL3360575T3 (pt)
PT (2) PT2493508T (pt)
RS (2) RS64190B1 (pt)
RU (2) RU2639087C2 (pt)
SI (2) SI3360575T1 (pt)
TR (1) TR201811600T4 (pt)
WO (1) WO2011051354A2 (pt)
ZA (1) ZA201202855B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US20120004204A1 (en) * 2010-07-02 2012-01-05 Biosante Pharmaceuticals, Inc. Methods for treating sexual dysfunction while decreasing cardiovascular risk
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2592370C9 (ru) * 2014-04-24 2016-08-27 Иван Иванович Дедов Средство на основе дегидроэпиандростерона, способ его применения
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
EP3370178A3 (en) 2017-03-03 2018-12-19 Tata Consultancy Services Limited Method and system for in silico testing of actives on human skin
RU2751037C1 (ru) * 2020-04-03 2021-07-07 Богдан Иванович Асатуров Фармацевтическая композиция на основе аутобиокомпонентов мочи человека для трансдермального применения с лечебной или косметической целью
CN111803469B (zh) * 2020-07-15 2022-08-12 浙江海阁堂医药有限公司 一种含雌二醇透皮吸收缓释贴片及其制备方法
CN113730339B (zh) * 2021-09-17 2023-08-22 中国药科大学 一种黄体酮缓释组合物及其应用
WO2023081539A1 (en) * 2021-11-08 2023-05-11 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1106455B (de) 1959-05-29 1961-05-10 Upjohn Co Salbengrundlage
FR2518879A1 (fr) 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
JPH0798935B2 (ja) 1987-11-25 1995-10-25 有限会社野々川商事 品質劣化防止剤
EP0364211B1 (en) 1988-10-11 1994-12-21 Shire Holdings Ltd. A percutaneous pharmaceutical preparation
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
DE69007886T2 (de) * 1989-07-21 1994-11-17 Izhak Blank Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung.
WO1992007590A1 (en) 1990-10-29 1992-05-14 Alza Corporation Transdermal contraceptive formulations, methods and devices
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
CN1135716A (zh) 1993-12-27 1996-11-13 阿克佐诺贝尔公司 经皮吸收的药用制剂
CN1106259A (zh) 1994-02-05 1995-08-09 日东制药株式会社 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
JP3081531B2 (ja) * 1996-03-22 2000-08-28 株式会社ヱビス科学研究所 手投げ消火液弾
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
IT1283102B1 (it) 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
RU2122396C1 (ru) 1996-07-12 1998-11-27 Валентина Александровна Андрюшина Биологически-активная добавка в косметические изделия
JP2001503062A (ja) 1996-10-30 2001-03-06 セラテック・インコーポレーテッド 透過促進剤としての乳酸の脂肪酸エステルの塩
KR100215027B1 (ko) 1997-01-27 1999-08-16 성재갑 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
CN1172674C (zh) 1997-11-10 2004-10-27 赛勒吉药物股份有限公司 促进渗透和减少刺激的系统
AU1689999A (en) 1997-12-25 1999-07-19 Daiichi Pharmaceutical Co., Ltd. Medicinal composition for percutaneous administration
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
WO2002011768A1 (en) 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
KR100416646B1 (ko) 2000-08-14 2004-02-05 구주제약주식회사 리도카인을 함유한 조루치료용 마이크로에멀젼 하이드로겔 제형의 약학 조성물
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
FR2814074B1 (fr) 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
JP2002212105A (ja) 2001-01-22 2002-07-31 Lion Corp 水性皮膚外用剤組成物
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
CA2484164C (en) * 2002-03-15 2009-12-29 Unimed Pharmaceuticals, Inc. Androgen pharmaceutical composition and method for treating depression
US6756050B2 (en) * 2002-06-28 2004-06-29 Ultra Biotech Limited Dietary supplements for improving memory
FR2848112B1 (fr) * 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
EP1952810B1 (en) * 2003-04-01 2014-01-08 Besins Healthcare Luxembourg SARL Treatment of breast cancer with 4-hydroxytamoxifen
US20070196325A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
DE602005011314D1 (de) * 2004-10-14 2009-01-08 Besins Int Lab 4-hydroxytamoxifengel-formulierungen
US20070082039A1 (en) * 2004-10-18 2007-04-12 Jones Gerald S Jr Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
WO2006110777A1 (en) 2005-04-12 2006-10-19 Unimed Pharmaceuticals, Inc. Method of treating or preventing bone deterioration or osteoporosis
KR20110108426A (ko) * 2005-04-25 2011-10-05 다우 파마슈티컬 사이언시즈 건선 치료를 위한 클로베타솔 분무 제형의 용도
WO2007038496A2 (en) * 2005-09-27 2007-04-05 Chemic Laboratories, Inc. Synthesis of fatty alcohol esters of hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
DK2373305T3 (en) * 2008-12-11 2017-05-15 Besins Healthcare Lu Sarl TRANSDERMAL PHARMACEUTICAL COMPOSITIONS INCLUDING A SERM
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents

Also Published As

Publication number Publication date
RS57596B1 (sr) 2018-11-30
RS64190B1 (sr) 2023-06-30
RU2012121708A (ru) 2013-12-10
ES2945590T3 (es) 2023-07-04
RU2017131709A3 (pt) 2020-10-21
EP3360575A1 (en) 2018-08-15
US11040043B2 (en) 2021-06-22
PT2493508T (pt) 2018-10-09
SI3360575T1 (sl) 2023-07-31
AU2010311523A1 (en) 2012-05-17
WO2011051354A3 (en) 2012-03-01
PL3360575T3 (pl) 2023-06-05
CA2778689C (en) 2019-06-11
ES2685313T3 (es) 2018-10-08
PL2493508T3 (pl) 2018-11-30
US20190160077A1 (en) 2019-05-30
EP2493508A2 (en) 2012-09-05
US10080760B2 (en) 2018-09-25
CN102686240B (zh) 2015-05-27
JP2013508444A (ja) 2013-03-07
ZA201202855B (en) 2013-06-26
SI2493508T1 (sl) 2018-10-30
LT2493508T (lt) 2018-10-25
DK3360575T3 (da) 2023-05-08
WO2011051354A4 (en) 2012-04-26
HUE039200T2 (hu) 2018-12-28
RU2017131709A (ru) 2019-02-06
WO2011051354A2 (en) 2011-05-05
AU2010311523B2 (en) 2013-10-17
HUE062026T2 (hu) 2023-09-28
CN102686240A (zh) 2012-09-19
LT3360575T (lt) 2023-06-12
TR201811600T4 (tr) 2018-09-21
BR112012010083A2 (pt) 2020-10-27
CY1120888T1 (el) 2019-12-11
RU2639087C2 (ru) 2017-12-19
BR112012010083B1 (pt) 2021-05-18
PT3360575T (pt) 2023-05-15
EP2493508B1 (en) 2018-07-18
DK2493508T3 (en) 2018-09-03
IL219236A0 (en) 2012-06-28
EP3360575B1 (en) 2023-04-19
IL219236A (en) 2016-02-29
CA2778689A1 (en) 2011-05-05
HRP20181346T1 (hr) 2018-10-19
FI3360575T3 (fi) 2023-05-05
JP5727494B2 (ja) 2015-06-03
HRP20230482T1 (hr) 2023-10-27
US20110098258A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
BR112012010083B8 (pt) Composição farmacêutica tópica de liberação sustentada e uso relacionado
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
BR112012018384A2 (pt) composição farmacêutica sólida com intensificadores e métodos de preparação da mesma.
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
BR112014027204A2 (pt) conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos
BR112014016550A8 (pt) formulação de liberação retardada para reduzir a frequência de urinação e método de uso da mesma
BR112014016661A8 (pt) formulação de liberação prolongada para reduzir a frequência de urinação e método de uso da mesma
BR112014020271A8 (pt) Composição farmacêutica e métodos para diminuir a frequência de micção em paciente
BRPI0923589A2 (pt) uso de uma composição espumável essencialmente livre de ingredientes farmaceuticamente ativos para o tratamento da pele humana.
CO6400186A2 (es) Tabletas de acetato de ulipristal
UA109785C2 (uk) Композиція фармацевтичного аерозолю, яка включає аналог вітаміну d і кортикостероїд
BR112015011430A2 (pt) composição para liberação imediata e prolongada
UY30762A1 (es) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2(dimetilamino) etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
CA2929865C (en) Sprayable topical carrier and composition comprising phosphatidylcholine
BRPI1015539A2 (pt) composições e métodos para tratamento de queimaduras
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
BR112013024824A2 (pt) ésteres isopentílicos para uso em composições cosméticas, dermatológicas ou farmacêuticas
BR112013006362A2 (pt) uso de compostos profármacos de éster de [3-(1-(1h-imidazol-4-il)etil)-2-metilfenil] metanol para reduzir a pressão intraocular, composição farmacêutica e artigo de fabricação
BR112015000321A2 (pt) formulações de laquinimod sem agente alcalinizante
BR112012029697A2 (pt) polissacarídeo da semente de tamarindo para uso no tratamento de doenças inflamatórias
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: BESINS HEALTHCARE LUXEMBOURG SARL (LU)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2628 DE 18/05/2021 QUANTO A QUALIFICACAO.